VALNEVA SE revenue breakdown overview

VALNEVA SE revenue for the last year amounted to 142.83 M CHF, the most of which — 142.84 M CHF — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines. The greatest contribution to the revenue figure was made by United States — last year it brought VALNEVA SE 30.63 M CHF, and the year before that — -23.56 M CHF.